The planned withdrawal follows the January failure of a Phase III trial to back up the study used for Lartruvo's accelerated approval. Following the announcement, the FDA and EMA recommended no new patients receive the drug.
Lilly announced last week that the Phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in the Phase II study that led to its accelerated approval.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
A Phase III trial of Lartruvo, which won accelerated approval for soft-tissue sarcoma in 2016, failed to confirm an overall survival benefit.